查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961051

全球基因组检测市场：依产品、检测类型、技术、适应症、最终用户和地区划分 - 市场规模、产业动态、机会分析和预测（2026-2035年）

Global Genomic Testing Market: By Offering, Testing Type, Technology, Indication, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 372 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球基因组检测市场正经历快速且显着的成长，反映出基因分析在医疗保健和研究领域日益成长的重要性。2025年，该市场规模约为 166.2亿美元，预计到2035年将显着成长至 413.4亿美元。这一预期成长意味着2026年至2035年的年复合成长率（CAGR）将达到 9.54%。推动这一令人瞩目的成长轨迹的关键因素有很多，其中以下一代定序（NGS）技术的进步最为重要。

推动市场扩张的另一个关键因素是对个人化医疗日益成长的需求。个人化医疗根据个人独特的基因谱客製化医疗方案。这种方法有望改善治疗效果并减少副作用，使基因组检测成为现代医疗保健的重要组成部分。此外，随着疾病早期检测（尤其是在肿瘤学领域）成为关注的焦点，基因组检测提供了在疾病早期阶段识别癌症生物标记和突变所需的工具，实现及时有效的干预。

市场趋势

基因组检测市场的特征是行业领导者和专业公司之间竞争激烈，它们透过策略联盟、併购等方式争夺市场领导地位。这种动态格局反映了每家公司为增强技术能力、扩大市场覆盖范围和丰富产品组合所做的努力。 Illumina 利用其先进的平台，满足各种临床和研究应用的需求，保持了其在高通量短读测序领域无可争议的领导地位。

然而，像 Oxford Nanopore 和 PacBio 这样的创新者则专注于长读定序技术，开闢了有利的细分市场，为短读定序方法无法解决的某些复杂基因组分析提供了独特的优势。在服务领域，Natera 和 Exact Sciences 等公司之间的竞争异常激烈，尤其是在有利的肿瘤检测市场。

Natera 在2024年第四季实现了令人瞩目的53%的营收成长，这凸显了市场领导者若能占据该细分市场的重要占有率，将获得多么巨大的收益。这一令人瞩目的成长不仅证实了肿瘤基因组检测的商业潜力，也激励着各公司采取积极的销售策略，并加大对行销活动的投入。

成长的核心驱动因子

基因组检测市场的快速扩张主要受慢性疾病的流行所驱动，其中癌症是推动市场成长的重要因素。根据世界卫生组织（WHO）2024年的资料，癌症仍然是全球主要死因之一，每年约有 2,000万新发病例。这惊人的数字凸显了癌症对全球带来的巨大健康负担，也进一步加剧了对先进诊断工具的迫切需求。展望未来，世界卫生组织预测，到2050年，癌症发生率将激增77%，这将促使人们对有效且精准的医疗干预措施的需求日益成长。为了应对这一日益严峻的挑战，肿瘤学家正日益利用基因组分析作为癌症治疗的关键组成部分。

新兴机会

次世代定序（NGS）已超越桑格定序和微阵列等传统技术，稳居基因组检测市场领先地位。与传统方法不同，NGS 具有惊人的高通量能力，能够在一次运行中同时对数百万条 DNA 链进行定序。这项技术飞跃彻底改变了基因组分析，提供了前所未有的速度和准确性，以及前所未有的成本效益。对 NGS 的需求在癌症基因治疗领域尤其显着，因为快速且准确的基因资讯对于开发标靶和个人化疗法非常重要。

最佳化障碍

基因组检测的高昂成本对全球众多患者而言构成重大障碍，可能减缓整体市场成长。儘管基因组技术取得了令人瞩目的进步，并在个人化医疗中展现出显着优势，但经济负担仍然是一项重大挑战，尤其是在医疗预算有限的中低收入国家。安装先进的定序设备、购买专用试剂以及聘请高素质专业人员的成本，都推高了基因组检测的价格。因此，许多可能受益于这些尖端诊断技术的患者无法负担相关费用，这可能会限制其广泛应用。

目录

第1章 研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第2章 研究方法

  • 定性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 依地区划分的一手调查受访者组成
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第3章 执行摘要：全球基因组检测市场

第4章 全球基因组检测市场概要

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 终端用户
  • 行业展望
    • 基因体资料分析
    • 基础设施和组织需求
    • 区域监管状况
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度、市场动态与趋势
      • 成长驱动因素
      • 限制因素
      • 挑战
      • 主要趋势
    • 影响评估新冠疫情对市场成长趋势的影响
    • 市场成长与展望
      • 市场收入估计与预测（2020-2035）
      • 价格趋势分析
    • 竞争格局概览
      • 市场集中度
      • 公司占有率分析（基于价值，2025）
      • 竞争格局图

    第5章 全球基因体检测市场分析：依提供内容

    • 主要发现
    • 市场规模及预测（2020-2035）
      • 系统与软体
      • 试剂与耗材
      • 服务

    第6章 全球基因组检测市场分析：依检测类型

    • 主要发现
    • 市场规模及预测，2020-2035
      • 定序解决方案
      • 微阵列解决方案

    第7章 全球基因体检测市场分析：依技术

    • 主要发现
    • 市场规模及预测，2020-2035
      • 蛋白质体学
      • 药物基因组学
      • 干细胞疗法
      • 克隆

    第8章 全球基因体检测市场分析：依适应症

    • 主要发现
    • 市场规模及预测，2020-2035
      • 癌症
      • 气喘
      • 糖尿病
      • 心臟病
      • 其他适应症

    第9章 全球基因体检测市场分析：依应用领域

    • 主要发现
    • 市场规模及预测（2020-2035）
      • 药物发现与开发
      • 疾病诊断
      • 农业生产
      • 其他

    第10章 全球基因组检测市场分析：依最终用户

    • 主要发现
    • 市场规模及预测（2020-2035）
    • 医院和诊所
    • 研究中心和学术机构机构
    • 製药和生技公司
    • 其他

第11章 全球基因体检测市场：交叉分析

  • 主要见解
  • 市场规模及预测（2020-2035）
    • 依产品、应用和最终用户划分

第12章 全球基因体检测市场分析：依地区划分

  • 主要见解
  • 市场规模及预测（2020-2035）
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美

第13章 北美基因体检测市场分析

第14章 欧洲基因组检测市场分析

第15章 亚太地区基因体检测市场分析

第16章 马来西亚基因组检测市场分析

第17章 泰国基因组检测市场分析

第18章 中东与非洲基因体检测市场分析

第19章 阿拉伯联合大公国（UAE）基因组检测市场分析

第20章 南美洲基因组检测市场分析

第21章 巴西基因组检测市场分析

第22章 公司简介

  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Eurofins Genomics
  • F. Hoffmann-La Roche
  • Illumina, Inc.
  • QIAGEN
  • Singular Genomics Systems, Inc.
  • Thermo Fisher Scientific, Inc.
  • 其他主要参与者
简介目录
Product Code: AA0423400

The global genomic testing market is undergoing rapid and substantial growth, reflecting the increasing importance of genetic analysis across healthcare and research sectors. In 2025, the market is valued at approximately USD 16.62 billion, but projections indicate a remarkable rise to USD 41.34 billion by 2035. This anticipated expansion corresponds to a robust compound annual growth rate (CAGR) of 9.54% over the forecast period from 2026 to 2035. Several key factors are driving this impressive growth trajectory, chief among them being technological advancements in next-generation sequencing (NGS).

Another significant contributor to market expansion is the rising demand for personalized medicine, which tailors medical treatment to an individual's unique genetic profile. This approach promises improved treatment outcomes and reduced side effects, making genomic testing an essential component of modern healthcare. Additionally, early disease detection, particularly in oncology, has become a critical focus, with genomic testing providing the tools necessary to identify cancer biomarkers and mutations at the earliest stages, thereby facilitating timely and targeted interventions.

Noteworthy Market Developments

The genomic testing market is characterized by intense competition, with a mix of well-established industry giants and specialized players vying for leadership through strategic alliances, mergers, and acquisitions. This dynamic landscape reflects companies' efforts to strengthen their technological capabilities, expand their market reach, and enhance their product portfolios. Illumina remains the undisputed leader in high-throughput short-read sequencing, leveraging its advanced platforms to serve a broad range of clinical and research applications.

However, other innovators like Oxford Nanopore and PacBio are successfully carving out profitable niches by focusing on long-read sequencing technologies, which offer unique advantages for certain complex genomic analyses that short-read methods cannot address. In the service arena, companies such as Natera and Exact Sciences are locked in fierce competition, particularly targeting the lucrative oncology testing market.

Natera's remarkable 53% revenue growth in the fourth quarter of 2024 exemplifies the substantial rewards available to market leaders who can capture significant volumes in this segment. This impressive growth not only underscores the commercial potential of oncology genomic testing but also motivates companies to adopt aggressive sales strategies and invest heavily in marketing efforts.

Core Growth Drivers

Chronic diseases serve as the primary driving force behind the rapid expansion of the genomic testing market. Among these diseases, cancer stands out as a particularly significant contributor to market growth. According to the World Health Organization's 2024 updates, cancer continues to be one of the leading causes of death worldwide, with roughly 20 million new cases diagnosed every year. This staggering figure highlights the immense global health burden posed by cancer, which in turn fuels the urgent need for advanced diagnostic tools. Looking ahead, the WHO projects a dramatic 77% increase in cancer incidence by the year 2050, underscoring the escalating demand for effective and precise medical interventions. In response to this growing challenge, oncologists are increasingly turning to genomic profiling as a critical component of cancer care.

Emerging Opportunity Trends

Next-Generation Sequencing (NGS) has firmly established itself as the dominant force within the genomic testing market, surpassing older technologies such as Sanger sequencing and microarrays. Unlike these traditional methods, NGS offers remarkably high-throughput capabilities, enabling the simultaneous sequencing of millions of DNA strands in a single run. This technological leap has revolutionized genomic analysis by providing unparalleled speed and accuracy, coupled with a level of cost-efficiency that was previously unattainable. The growing demand for NGS is especially pronounced in the field of cancer gene therapy, where rapid and precise genetic information is crucial for developing targeted treatments and personalized therapies.

Barriers to Optimization

The high costs associated with genomic testing present a significant barrier to accessibility for a broad range of patient populations around the world, potentially slowing the overall growth of the market. Despite the tremendous advancements in genomic technologies and their proven benefits in personalized medicine, the financial burden remains a critical challenge, particularly in low- and middle-income countries where healthcare budgets are limited. The expense of acquiring sophisticated sequencing equipment, purchasing proprietary reagents, and employing highly specialized personnel contributes to the elevated price of genomic tests. As a result, many patients who could benefit from these cutting-edge diagnostics may find them out of reach, limiting the widespread adoption of genomic testing.

Detailed Market Segmentation

By Offerings, the Reagents and Consumables segment holds a commanding position in the genomic testing market, capturing a substantial 46.7% share. This dominance is deeply rooted in the industry's strategic adoption of the "razor-and-blade" business model, which has been structurally engineered by leading companies to ensure sustained revenue streams. Under this model, the initial sale of sequencing equipment-the "razor"-is complemented by the ongoing, mandatory purchase of proprietary reagents and consumables-the "blades"-which are essential for the operation of these devices. Once a sequencing instrument is installed in a laboratory or clinical setting, it creates a continuous demand for these consumables, generating exponential recurring revenue for manufacturers.

By Testing Type, Sequencing Solutions, particularly Next-Generation Sequencing (NGS), dominate the genomic testing market by commanding an overwhelming 66.73% share. This dominance reflects a significant shift in the role of sequencing technologies, which have evolved from being primarily research tools to becoming the undisputed standard of care in clinical diagnostics. The widespread adoption of NGS is a testament to its unparalleled ability to provide comprehensive, high-resolution genetic information that is critical for accurate diagnosis and personalized treatment planning. One of the key drivers behind this massive market share is the explosive commercial growth of liquid biopsy and Minimum Residual Disease (MRD) testing.

By Applications, the Drug Development and Discovery application stands out as the most significant driver of revenue within the global genomic testing market, accounting for over 46% of the total market income. This dominant position underscores the critical role that genomic testing plays in the pharmaceutical industry's research and development efforts. Pharmaceutical companies increasingly rely on genomic data as a fundamental risk-mitigation tool to navigate the complexities and uncertainties inherent in their multi-billion-dollar R&D pipelines. By integrating genomic insights into the drug discovery process, these companies can better identify promising therapeutic targets, optimize clinical trial designs, and predict patient responses more accurately.

By Technology, stem cell therapy technology holds a commanding position in the genomic testing market, capturing a substantial 42.4% share. This dominance stems from the critical role that genomic testing plays in the manufacturing process of Cell and Gene Therapies (CGT), where it is not merely an optional step but a strict regulatory requirement. Regulatory bodies such as the FDA have established comprehensive guidelines that mandate the use of highly sensitive genomic testing techniques to ensure the safety and efficacy of these advanced therapies. Specifically, the FDA's finalized guidance on human gene therapy products requires manufacturers to rigorously screen for potential "off-target" genetic edits and chromosomal rearrangements.

Segment Breakdown

By Offering:

  • System and Software
  • Reagents & Consumables
  • Services
  • DTC Genomic Testing Service
  • Sale of genomic data

By Testing Type:

  • Sequencing Solution
  • DNA Sequencing
  • RNA Sequencing
  • Methylation Sequencing
  • NGS Library Preparation
  • Sequencing Data Analysis
  • Others
  • Microarray Solution
  • Human Genotyping with Arrays
  • Non-Human Genotyping with Arrays
  • Methylation Array Analysis
  • Microarray Data Analysis
  • Others

By Technology:

  • Proteomics
  • Pharmacogenomics
  • Stem Cell Therapy
  • Cloning

By Indication:

  • Cancer
  • Asthma
  • Diabetes
  • Hearth Diseases
  • Other Indication

By Application:

  • Drug Discovery & Development
  • Disease Diagnosis
  • Agricultural Production
  • Others

By End-User:

  • Hospitals & Clinics
  • Research Centers & Academic Institutions
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region:

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • Malaysia
  • Thailand
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America currently holds the largest share of the genomic testing market, commanding approximately 35% of the global market. This dominant position is largely attributed to a favorable reimbursement landscape that encourages widespread adoption of genomic testing across healthcare providers. High levels of healthcare spending in the region further support market growth, enabling greater investment in advanced diagnostic technologies and infrastructure. The United States, in particular, plays a pivotal role in driving this market leadership.
  • Additionally, strong governmental support acts as a critical catalyst for growth. For example, the National Institutes of Health (NIH) has significantly contributed to advancing genomic research through initiatives like the All of Us Research Program, which by February 2025 had released data on 633,000 participants. This large-scale data resource not only accelerates scientific discovery but also helps integrate genomic insights into clinical practice, further reinforcing North America's leading position in the genomic testing market.

Leading Market Participants

  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Eurofins Genomics
  • F. Hoffmann-La Roche
  • Illumina, Inc.
  • QIAGEN
  • Singular Genomics Systems, Inc.
  • Thermo Fisher Scientific, Inc.
  • Other Prominent players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Genomic Testing Market

Chapter 4. Global Genomic Testing Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Raw Material Supplier
    • 4.1.2. Manufacturers
    • 4.1.3. Distributors
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Genomic Data Analysis
    • 4.2.2. Requisite infrastructure and organization for the entering
    • 4.2.3. Regulatory Landscape W.R.T Region
      • 4.2.3.1. North America Regulations/Laws
      • 4.2.3.2. Europe Regulations/Laws
      • 4.2.3.3. Asia Pacific Regulations/Laws
      • 4.2.3.4. South America Regulations/Laws
      • 4.2.3.5. Middle East & Africa Regulations/Laws
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2035
    • 4.7.2. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2025
    • 4.8.3. Competitor Mapping

Chapter 5. Global Genomic Testing Market Analysis, By Offering

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 5.2.1. System and Software
    • 5.2.2. Reagents & Consumables
    • 5.2.3. Services
      • 5.2.3.1. DTC Genomic Testing Service
      • 5.2.3.2. Sale of genomic data

Chapter 6. Global Genomic Testing Market Analysis, By Testing Type

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 6.2.1. Sequencing Solution
      • 6.2.1.1. DNA Sequencing
      • 6.2.1.2. RNA Sequencing
      • 6.2.1.3. Methylation Sequencing
      • 6.2.1.4. NGS Library Preparation
      • 6.2.1.5. Sequencing Data Analysis
      • 6.2.1.6. Others
    • 6.2.2. Microarray Solution
      • 6.2.2.1. Human Genotyping with Arrays
      • 6.2.2.2. Non-Human Genotyping with Arrays
      • 6.2.2.3. Methylation Array Analysis
      • 6.2.2.4. Microarray Data Analysis
      • 6.2.2.5. Others

Chapter 7. Global Genomic Testing Market Analysis, By Technology

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 7.2.1. Proteomics
    • 7.2.2. Pharmacogenomics
    • 7.2.3. Stem Cell Therapy
    • 7.2.4. Cloning

Chapter 8. Global Genomic Testing Market Analysis, By Indication

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 8.2.1. Cancer
    • 8.2.2. Asthma
    • 8.2.3. Diabetes
    • 8.2.4. Hearth Diseases
    • 8.2.5. Other Indication

Chapter 9. Global Genomic Testing Market Analysis, By Application

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 9.2.1. Drug Discovery & Development
    • 9.2.2. Disease Diagnosis
    • 9.2.3. Agricultural Production
    • 9.2.4. Others

Chapter 10. Global Genomic Testing Market Analysis, By End User

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 10.2.1. Hospitals & Clinics
    • 10.2.2. Research Centers & Academic Institutions
    • 10.2.3. Pharmaceutical & Biotechnology Companies
    • 10.2.4. Others

Chapter 11. Global Genomic Testing Market, Cross Analysis

  • 1.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 11.2.1. By Offering, By Application, By End User

Chapter 12. Global Genomic Testing Market Analysis, By Region

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 12.2.1. North America
      • 12.2.1.1. The U.S.
      • 12.2.1.2. Canada
      • 12.2.1.3. Mexico
    • 12.2.2. Europe
      • 12.2.2.1. Western Europe
        • 12.2.2.1.1. The UK
        • 12.2.2.1.2. Germany
        • 12.2.2.1.3. France
        • 12.2.2.1.4. Italy
        • 12.2.2.1.5. Spain
        • 12.2.2.1.6. Rest of Western Europe
      • 12.2.2.2. Eastern Europe
        • 12.2.2.2.1. Poland
        • 12.2.2.2.2. Russia
        • 12.2.2.2.3. Rest of Eastern Europe
    • 12.2.3. Asia Pacific
      • 12.2.3.1. China
      • 12.2.3.2. India
      • 12.2.3.3. Japan
      • 12.2.3.4. South Korea
      • 12.2.3.5. Australia & New Zealand
      • 12.2.3.6. ASEAN
      • 12.2.3.7. Rest of Asia Pacific
    • 12.2.4. Middle East & Africa
      • 12.2.4.1. UAE
      • 12.2.4.2. Saudi Arabia
      • 12.2.4.3. South Africa
      • 12.2.4.4. Rest of MEA
    • 12.2.5. South America
      • 12.2.5.1. Argentina
      • 12.2.5.2. Brazil
      • 12.2.5.3. Rest of South America

Chapter 13. North America Genomic Testing Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 13.2.1. By Offering
    • 13.2.2. By Testing Type
    • 13.2.3. By Technology
    • 13.2.4. By Indication
    • 13.2.5. By Application
    • 13.2.6. By End User
    • 13.2.7. Cross Analysis
    • 13.2.8. By Country

Chapter 14. Europe Genomic Testing Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 14.2.1. By Offering
    • 14.2.2. By Testing Type
    • 14.2.3. By Technology
    • 14.2.4. By Indication
    • 14.2.5. By Application
    • 14.2.6. By End User
    • 14.2.7. Cross Analysis
    • 14.2.8. By Country

Chapter 15. Asia Pacific Genomic Testing Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 15.2.1. By Offering
    • 15.2.2. By Testing Type
    • 15.2.3. By Technology
    • 15.2.4. By Indication
    • 15.2.5. By Application
    • 15.2.6. By End User
    • 15.2.7. Cross Analysis
    • 15.2.8. By Country

Chapter 16. Malaysia Genomic Testing Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 16.2.1. By Offering
    • 16.2.2. By Testing Type
    • 16.2.3. By Technology
    • 16.2.4. By Indication
    • 16.2.5. By Application
    • 16.2.6. By End User
    • 16.2.7. Cross Analysis

Chapter 17. Thailand Genomic Testing Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 17.2.1. By Offering
    • 17.2.2. By Testing Type
    • 17.2.4. By Indication
    • 17.2.5. By Application
    • 17.2.6. By End User
    • 17.2.7. Cross Analysis

Chapter 18. Middle East and Africa Genomic Testing Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 18.2.1. By Offering
    • 18.2.2. By Testing Type
    • 18.2.3. By Technology
    • 18.2.4. By Indication
    • 18.2.5. By Application
    • 18.2.6. By End User
    • 18.2.7. Cross Analysis
    • 18.2.8. By Country

Chapter 19. UAE Genomic Testing Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 19.2.1. By Offering
    • 19.2.2. By Testing Type
    • 19.2.3. By Technology
    • 19.2.4. By Indication
    • 19.2.5. By Application
    • 19.2.6. By End User
    • 19.2.7. Cross Analysis

Chapter 20. South America Genomic Testing Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 20.2.1. By Offering
    • 20.2.2. By Testing Type
    • 20.2.3. By Technology
    • 20.2.4. By Indication
    • 20.2.5. By Application
    • 20.2.6. By End User
    • 20.2.7. Cross Analysis
    • 20.2.8. By Country

Chapter 21. Brazil Genomic Testing Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 21.2.1. By Offering
    • 21.2.2. By Testing Type
    • 21.2.3. By Technology
    • 21.2.4. By Indication
    • 21.2.5. By Application
    • 21.2.6. By End User
    • 21.2.7. Cross Analysis

Chapter 22. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 22.1. Agilent Technologies, Inc.
  • 22.2. BGI Group
  • 22.3. Bio-Rad Laboratories
  • 22.4. Danaher Corporation
  • 22.5. Eurofins Genomics
  • 22.6. F. Hoffmann-La Roche
  • 22.7. Illumina, Inc.
  • 22.8. QIAGEN
  • 22.9. Singular Genomics Systems, Inc.
  • 22.10. Thermo Fisher Scientific, Inc.
  • 22.11. Other Prominent players